1. Home
  2. TENX vs VHCP Comparison

TENX vs VHCP Comparison

Compare TENX & VHCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.64

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

VHCP

Vine Hill Capital Investment Corp. II Class A Ordinary Shares

N/A

Current Price

$10.01

Market Cap

303.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
VHCP
Founded
1967
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
303.6M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
VHCP
Price
$13.64
$10.01
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
898.1K
8.3K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$9.89
52 Week High
$18.38
$10.05

Technical Indicators

Market Signals
Indicator
TENX
VHCP
Relative Strength Index (RSI) 67.28 59.28
Support Level $13.16 $9.89
Resistance Level $14.15 N/A
Average True Range (ATR) 0.72 0.00
MACD 0.30 -0.00
Stochastic Oscillator 99.40 100.00

Price Performance

Historical Comparison
TENX
VHCP

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About VHCP Vine Hill Capital Investment Corp. II Class A Ordinary Shares

Vine Hill Capital Investment Corp II is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: